DelveInsight’s Urothelial Carcinoma Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the urothelial carcinoma pipeline domain.
Some of the essential takeaways from the Urothelial Carcinoma Pipeline report:
- DelveInsight’s urothelial carcinoma pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies
- Some of the key urothelial carcinoma pipeline companies working to develop potential drug candidates to improve the urothelial carcinoma treatment scenario include Shandong TheraWisdom Biopharma Co., Ltd., Ikena Oncology, Ocellaris Pharma, Inc., Bayer, 4D Pharma PLC, MedPacto, QED Therapeutics, Bristol-Myers Squibb, Kyowa Kirin Pharmaceutical Development, Vyriad,Inc, Basilea Pharmaceutica, Pfizer, Daiichi Sankyo, Janssen Research & Development, LLC, Eli Lilly and Company, InnoCare Pharma, Kinnate Biopharma, Clovis Oncology, Gritstone Oncology, Xennials Therapeutics, Genome and Company , Exelixis, Atreca, Zentalis Pharmaceuticals, Celldex Therapeutics Inc , Nurix Therapeutics, Inc., Lipac Oncology LLC, TesoRx Pharma, LLC, Adaptimmune Therapeutics, Helsinn Group, Bicycle Therapeutics, Scholar Rock, Inc., Janux Therapeutics, Checkpoint Therapeutics, Inc., BioAtla, Inc., Cybrexa Therapeutics, Eisai Inc., Incyte Corporation, Shattuck Labs, Inc., Tempest Therapeutics, RAPT Therapeutics, Inc., Nektar Therapeutics, TAIHO PHARMACEUTICAL, Jazz Pharmaceuticals, Tyra Biosciences, Rubius Therapeutics, MacroGenics, BioNTech SE, Sorrento, and several others
- Essential urothelial carcinoma therapies such as OC-001, IK-175, MRx 518, Rogaratinib, Vactosertib, Infigratinib, TWP-101, Ipilimumab, KHK 2455, MV-NIS, Derazantinib, Sasanlimab, Trastuzumab deruxtecan, TAR-200, Ramucirumab, ICP-192, KIN-3248, Rucaparib, GRANITE 001, NTX-301, GEN-001, XL092, ATRC-101, ZN-c3, CDX-527, NX-1607, TSD-001, CK-301, BA3071, CBX-12, E7130, INCB099280, SL-279252, TPST-1495, FLX475, NKTR-255, TAS0313, Lurbinectedin, TYRA-300, RTX-224, Enoblituzumab, GEN1046, Sti-3031, etc
- In May 2022, Exelixis, Inc. announced detailed results from multiple cohorts of Phase Ib COSMIC-021 trials of cabozantinib (CABOMETYX^®) as a monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The company announced that they would be presenting the data from urothelial carcinoma (UC) cohorts 3, 4, and 5 and from non-small cell lung cancer (NSCLC) cohorts 7 and 20 during oral abstract sessions at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, June 3–7
- In May 2022, Kinnate Biopharma Inc. announced the presentation of the design and rationale of a Phase I trial-in-progress (KIN-4802, NCT05242822) evaluating the company’s pan-FGFR inhibitor product candidate, KIN-3248. The company announced that they would be presenting the details during a poster session on June 6, 2022, at the Annual Meeting of the American Society of Clinical Oncology (ASCO). In April 2022, Ikena Oncology, Inc. announced that it would be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The presentations will include overviews of the clinical trials for Ikena’s novel TEAD inhibitor, IK-930, and aryl hydrocarbon receptor (AHR) antagonist, IK-175
Request a sample and discover more about the report offerings @ Urothelial Carcinoma Emerging Therapies
The urothelial carcinoma pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage urothelial carcinoma products, inactive and dormant assets, and a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the urothelial carcinoma pipeline landscape.
Urothelial Carcinoma Overview
Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is the most common type of bladder cancer. In fact, if you have bladder cancer, it is almost certain to be a urothelial carcinoma. These cancers start in the urothelial cells that line the inside of the bladder. Urothelial cells also line other parts of the urinary tract, such as the part of the kidney that connects to the ureter (called the renal pelvis), the ureters, and the urethra. People with bladder cancer sometimes have tumors in these places, too, so all of the urinary tracts need to be checked for tumors.
Understand more about the prevalent diabetic disease @ Urothelial Carcinoma Pipeline Drugs Assessment
Urothelial Carcinoma Therapeutics Assessment
The Urothelial Carcinoma Pipeline report proffers an integral view of the urothelial carcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Urothelial Carcinoma Pipeline Report
- Coverage: Global
- Therapeutic assessment by urothelial carcinoma product type: mono, combination, mono/combination
- Therapeutic assessment by urothelial carcinoma clinical stages: Discovery, preclinical, Phase I, Phase II, Phase III, preregistration, inactive candidates
- Therapeutics assessment by urothelial carcinoma route of administration: oral, parenteral, intravenous, subcutaneous, topical
- Therapeutics assessment by urothelial carcinoma molecule type: monoclonal antibody, peptides, polymer, small molecule, gene therapy
- Therapeutics assessment by urothelial carcinoma mechanism of action: Transforming growth factor-beta type I receptor antagonist, Aryl hydrocarbon receptor antagonist, Type 3 fibroblast growth factor receptor antagonist; Type 4 fibroblast growth factor receptor antagonist; Type-2 fibroblast growth factor receptor antagonist, Type 1 fibroblast growth factor receptor antagonist; Toll-like receptor 5 agonist, NF-kappa B modulator, Bacteria replacement; Prostaglandin E EP2 receptor antagonist; Natural killer cell stimulant; CCR4 receptor antagonist
- Key urothelial carcinoma companies: Shandong TheraWisdom Biopharma Co., Ltd., Ikena Oncology, Ocellaris Pharma, Inc., Bayer, 4D Pharma PLC, MedPacto, QED Therapeutics, Bristol-Myers Squibb, Kyowa Kirin Pharmaceutical Development, Vyriad,Inc, Basilea Pharmaceutica, Pfizer, Daiichi Sankyo, Janssen Research & Development, LLC, Eli Lilly and Company, InnoCare Pharma, Kinnate Biopharma, Clovis Oncology, Gritstone Oncology, Xennials Therapeutics, Genome and Company , Exelixis, Atreca, Zentalis Pharmaceuticals, Celldex Therapeutics Inc , Nurix Therapeutics, Inc., Lipac Oncology LLC, TesoRx Pharma, LLC, Adaptimmune Therapeutics, Helsinn Group, Bicycle Therapeutica, Scholar Rock, Inc., Janux Therapeutics, Checkpoint Therapeutics, Inc., BioAtla, Inc., Cybrexa Therapeutics, Eisai Inc., Incyte Corporation, Shattuck Labs, Inc., Tempest Therapeutics, RAPT Therapeutics, Inc., Nektar Therapeutics, TAIHO PHARMACEUTICAL, Jazz Pharmaceuticals, Tyra Biosciences, Rubius Therapeutics, MacroGenics, BioNTech SE, Sorrento, and several others
- Key urothelial carcinoma pipeline therapies: OC-001, IK-175, MRx 518, Rogaratinib, Vactosertib, Infigratinib, TWP-101, Ipilimumab, KHK 2455, MV-NIS, Derazantinib, Sasanlimab, Trastuzumab deruxtecan, TAR-200, Ramucirumab, ICP-192, KIN-3248, Rucaparib, GRANITE 001, NTX-301, GEN-001, XL092, ATRC-101, ZN-c3, CDX-527, NX-1607, TSD-001, CK-301, BA3071, CBX-12, E7130, INCB099280, SL-279252, TPST-1495, FLX475, NKTR-255, TAS0313, Lurbinectedin, TYRA-300, RTX-224, Enoblituzumab, GEN1046, Sti-3031, and many others
Dive deep into rich insights for emerging therapies and assessment, visit @ Urothelial Carcinoma Pipeline Drugs
Table of Content
- Introduction
- Executive Summary
- Urothelial Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Urothelial Carcinoma– DelveInsight’s Analytical Perspective
- Mid Stage Products (Phase III)
- Cetrelimab: Janssen Research and Development
- Mid Stage Products (Phase II)
- Vactosertib: MedPacto
- Early Stage Products (Phase I/II)
- Drug name: Company name
- Early Stage Products (Phase I)
- MV NIS: Vyriad
- Preclinical Stage Products
- Drug name: Company name
- Inactive Products
- Urothelial Carcinoma Key Companies
- Urothelial Carcinoma Key Products
- Urothelial Carcinoma- Unmet Needs
- Urothelial Carcinoma- Market Drivers and Barriers
- Urothelial Carcinoma- Future Perspectives and Conclusion
- Urothelial Carcinoma Analyst Views
- Urothelial Carcinoma Key Companies
- Appendix
For further information on the Urothelial carcinoma current pipeline therapeutics, reach out @ Urothelial Carcinoma Ongoing Clinical Trials
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/